Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.

Gutierrez-Cosío S, de la Rica L, Ballestar E, Santamaría C, Sánchez-Abarca LI, Caballero-Velazquez T, Blanco B, Calderón C, Herrero-Sánchez C, Carrancio S, Ciudad L, Cañizo C, San Miguel JF, Pérez-Simón JA.

Leuk Res. 2012 Jul;36(7):895-9. doi: 10.1016/j.leukres.2012.02.030.

PMID:
22503131
2.

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.

Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N.

Am J Hematol. 2011 Nov;86(11):918-22. doi: 10.1002/ajh.22141.

3.

Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.

Ortmann CA, Eisele L, Nückel H, Klein-Hitpass L, Führer A, Dührsen U, Zeschnigk M.

Ann Hematol. 2008 Oct;87(10):809-18. doi: 10.1007/s00277-008-0514-8.

PMID:
18587578
4.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.

Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels BM, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf TH, Atanackovic D.

Leuk Res. 2010 Dec;34(12):1647-55. doi: 10.1016/j.leukres.2010.03.039.

PMID:
20409582
5.

Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.

Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B.

Cancer Genet Cytogenet. 2002 Mar;133(2):118-23.

PMID:
11943337
6.

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.

Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C, Lübbert M.

Leuk Res. 2013 Feb;37(2):190-6. doi: 10.1016/j.leukres.2012.10.015.

PMID:
23158571
7.

MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.

Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, Kang HY, Yan GT, Wang LL, Yu L.

Oncogene. 2011 Aug 4;30(31):3416-28. doi: 10.1038/onc.2011.62.

PMID:
21399664
8.

Epigenetic regulation of PRAME gene in chronic myeloid leukemia.

Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Jose-Eneriz ES, Garate L, Cordeu L, Cervantes F, Prosper F, Heiniger A, Torres A.

Leuk Res. 2007 Nov;31(11):1521-8.

PMID:
17382387
9.

Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.

Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP.

Genes Chromosomes Cancer. 2007 Sep;46(9):796-804.

PMID:
17534929
10.

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L.

Blood. 2006 Dec 15;108(13):4109-17.

11.

Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.

de Jonge HJ, Woolthuis CM, Vos AZ, Mulder A, van den Berg E, Kluin PM, van der Weide K, de Bont ES, Huls G, Vellenga E, Schuringa JJ.

Leukemia. 2011 Dec;25(12):1825-33. doi: 10.1038/leu.2011.172.

PMID:
21760593
13.

Simultaneous expression of different immunogenic antigens in acute myeloid leukemia.

Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M.

Exp Hematol. 2000 Dec;28(12):1413-22.

PMID:
11146163
14.

[Quantification of the PRAME transcripts in patients with acute myeloid leukemia].

Zhu ZH, Qian J, Lin J, Yao DM, Qian Z, Wang YL, Chen Q, Han LX, Xiao G.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Apr;27(2):149-52. doi: 10.3760/cma.j.issn.1003-9406.2010.02.007. Chinese.

PMID:
20376794
15.

Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21).

Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Turker A, Goldstone AH, Burnett A.

Blood. 1996 Feb 1;87(3):1162-9.

16.

Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.

Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C, Westra AH, Ossenkoppele GJ, Zweegman S, Schuurhuis GJ.

Stem Cells. 2008 Dec;26(12):3059-67. doi: 10.1634/stemcells.2007-0861.

17.

Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.

Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Wang L, Yu L.

PLoS One. 2013 Aug 5;8(8):e70522. doi: 10.1371/journal.pone.0070522.

18.

[PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].

Qin YZ, Li JL, Zhu HH, Li LD, Chang Y, Hao L, Wang YZ, Jiang B, Lu XJ, Liu YR, Huang XJ, Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jul;29(7):441-5. Chinese.

PMID:
19035174
19.

Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.

Spanaki A, Perdikogianni C, Linardakis E, Kalmanti M.

Leuk Res. 2007 May;31(5):639-42.

PMID:
16860864
20.

Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B.

Itonaga H, Imanishi D, Wong YF, Sato S, Ando K, Sawayama Y, Sasaki D, Tsuruda K, Hasegawa H, Imaizumi Y, Taguchi J, Tsushima H, Yoshida S, Fukushima T, Hata T, Moriuchi Y, Yanagihara K, Miyazaki Y.

Leukemia. 2014 Jul;28(7):1459-66. doi: 10.1038/leu.2014.15.

PMID:
24457336

Supplemental Content

Support Center